

Study	Country	Study design	Setting	Sample size	Cancer type	Risk assessment methodology	Follow-up
Stojadinovic 2008 ³²	US	NRSI (prospective)	Multicentre, international screening trial in a tertiary care setting	Intervention: 1751 Control: 390	Breast	Point-of-care electrical impedance scan of breast tissue	High: Informed findings and given risk-appropriate follow-up Low: Routine screening
Venturini 2013 ³⁶	Italy	NRSI (prospective)	Single-centre in a primary care setting	Intervention: 1666 Control: NA	Breast	Point-of-care mammogram results Clinical questionnaire calculating Gail model score	High: Referred for both ultrasound and contrasted MRI Moderate: Mammography and ultrasound Low: Mammography only
Budal 2014 ⁵⁵	Norway	NRSI (prospective)	Multicentre, national screening programme	Intervention: 1744 Control: NA	Cervical	Point-of-care high-risk HPV testing	High: Immediate colposcopy Low: Routine screening
Grönberg 2015 ¹⁹	Sweden	NRSI (prospective)	Multicentre, national screening trial in a primary care setting	Intervention: 47,688 Control: NA	Prostate	Utilised STHLM3 model Plasma protein biomarkers related to PCa Genetic testing for high-risk polymorphisms Prostate examination results Clinical questionnaire eliciting age, family history of cancer and recent prostate biopsy findings	High: Prostate biopsy and urologist referral Low: No biopsy
Pedersen 2015 ³⁹	Denmark	RCT	Single-centre screening trial in a primary care setting	Intervention: 2052 Control: 2052	Lung	Low-dose CT scan Self-reported age, smoking history and previous COPD diagnosis	High: Annual screening by low-dose CT scans Low: Return to routine screening
Field 2016 ⁴⁹	UK	RCT	Multicentre, national screening trial in a cancer specialist centre setting	Intervention: 2028 Control: 2027	Lung	Self-reported age, smoking history and previous medical record	High: Immediate referral to multidisciplinary team Moderate: Follow-up CT at 3 and 12 months

Study	Country	Study design	Setting	Sample size	Cancer type	Risk assessment methodology	Follow-up
							Average: Follow-up CT at 12 months
							Low: No follow-up
Yen 2016 ²⁹	Taiwan	NRSI (retrospective)	Multicentre, national breast cancer screening programme	Intervention: 1,429,890 Control: NA	Breast	Clinical questionnaire eliciting family history of cancer, menstrual and reproductive history	High: Biennial mammography Low: Return to routine screening
Yousaf-Khan 2016 ²⁸	Netherlands	NRSI (prospective)	Multicentre, international screening trial in a community setting	Intervention: 5297 Control: NA	Lung	Point-of-care CT imaging	High: Referred to pulmonologist for diagnostic workup Moderate: Low-dose follow-up CT and VDT Low: Next regular screening
Guivatchian 2017 ⁴⁷	US	NRSI (prospective)	Single-centre screening trial in a tertiary care setting	Intervention: 700 Control: NA	Colorectal	Clinical questionnaire eliciting past personal history of cancer, polyp history and family history of polyps	High: Genomic evaluation
Swenen 2017 ³⁵	Belgium	NRSI (prospective)	Single-centre screening trial in a cancer specialist centre setting	Intervention: 11,123 Control: 2008	Breast	Clinical breast examination	High: Ultrasound
						Clinical questionnaire eliciting family and personal history of cancer	Low: Biennial mammogram
Li 2018 ⁴⁵	China	NRSI (prospective)	Single-centre, community mass screening programme	Intervention: 891,199 Control: NA	Colorectal	FIT test results	High: Colonoscopy
						Clinical questionnaire eliciting biodata, CRC-related symptoms and family history of CRC	Low: FIT
Dwarte 2019 ⁵⁰	Australia	NRSI (prospective)	Multicentre, national in a cancer specialist centre setting	Intervention: 102 Control: NA	Pancreatic	Endoscopic ultrasound results Blood test results	High: Close surveillance or treatment
						Genetic risk assessment using PancPRO, a questionnaire eliciting family history of cancer	Average: Yearly endoscopic ultrasound for 5 years

Study	Country	Study design	Setting	Sample size	Cancer type	Risk assessment methodology	Follow-up
Chen 2021 ⁵⁴	China	NRSI (prospective)	Multicentre, national screening programme in a community setting	Intervention: 53,382 Control: NA	Nasopharyngeal	Epstein-Barr virus serology results	High: Endoscopy Moderate: Annual blood testing Low: 5-yearly visit
Loopik 2021 ⁴⁴	Netherlands	NRSI (retrospective)	Multicentre, national screening programme in a primary care setting	Intervention: 619,253 Control: 769,442	Cervical	Point-of-care high-risk HPV test	High: Cytologic assessment on physician-sampled material and colposcopy Low: Return to routine screening
Nordström 2021 ⁴¹	Sweden	RCT	Multicentre, national screening trial in a community setting	Intervention: 1372 Control: 921	Prostate	Utilised STHLM3 model Plasma protein biomarkers related to PCa Genetic testing for high-risk polymorphisms Prostate examination results Clinical questionnaire eliciting age, family history of cancer and recent prostate biopsy findings	High: Sytematic and MRI-guided biopsy Low: Return to routine screening
Reesink 2021 ³⁷	Netherlands	NRSI (prospective)	Single-centre screening trial in a primary care setting	Intervention: 496 Control: NA	Prostate	MRI-imaging of prostate with PI-RADS staging European Randomized Study of Screening for Prostate Cancer risk calculation, utilising age, family history of PCa, related symptoms and PSA levels	High: Targeted and systematic biopsy Moderate: Sytematic biopsy Low: No biopsy
Xu 2021 ³⁰	China	NRSI (prospective)	Single-centre screening trial in a tertiary care setting	Intervention: 2444 Control: NA	Cervical	Cytology with reference to Bethesda grading Point-of-care DH3 HPV test assay	High: Colposcopy and biopsies Moderate: Rescreening by cytology every 12 months

Study	Country	Study design	Setting	Sample size	Cancer type	Risk assessment methodology	Follow-up
Adeoye 2022 ⁵⁷	Hong Kong	NRSI (prospective)	Single-centre screening trial in a community setting	Intervention: 100 Control: 881	Oral	Visual oral examination	High: Screening required
						Clinical questionnaire assessing family history, biodata, lifestyle factors, past medical history and related symptoms	Moderate: Screening on availability
							Low: Routine opportunistic screening
Kortlever 2022 ⁴⁶	Netherlands	RCT	Multicentre, national screening programme in a primary care setting	Intervention: 11,364 Control: 11,384	Colorectal	Clinical questionnaire eliciting smoking history, recent FIT results, family history of cancer and biodata	High: Colonoscopy Low: Return to routine screening
Michael 2022 ⁴²	US	NRSI (retrospective)	Multicentre, national screening trial in a primary care setting	Intervention: 564 Control: NA	Prostate	PSA test results Clinical questionnaire eliciting age, race and family history of cancer	High: Urology referral
Trevena 2022 ³³	Australia	RCT	Multicentre, national in a primary care setting	Intervention: 12,420 Control: 12,880	Colorectal	Clinical questionnaire eliciting family history of cancer	High: Assessment by familial cancer service or colonoscopy
							Moderate: Colonoscopy every 5 years
							Low: FOBT every 2 years
Chen 2023 ⁵³	China	RCT	Multicentre, national community screening programme	Intervention: 3937 Control: 7858	Colorectal	Clinical questionnaire to calculate Asia-Pacific Colorectal Screening Score	High: Colonoscopy Low: FIT screening and routine screening
Chiu 2023 ⁵²	China	NRSI (prospective)	Single-centre screening trial in a primary care setting	Intervention: 1536 Control: NA	Prostate	PSA test scores	High: MRI-guided and systematic prostate biopsy
						Prostate Health Index scores	Moderate: Systematic prostate biopsy
						MRI prostate findings	Average: No biopsy
Emery 2023 ¹⁸	Australia	RCT	Multicentre, national screening trial in a primary care setting	Intervention: 369 Control: 365	Colorectal	Clinical questionnaire assessing family history, biodata, lifestyle factors, past medical history and related symptoms	High: Referral to familial cancer centre for formal assessment
							Moderate: Colonoscopy every 5 years

Study	Country	Study design	Setting	Sample size	Cancer type	Risk assessment methodology	Follow-up
							Average: iFOBT every 2 years
Gareth Evans 2023 ⁴⁸	UK	NRCT	Multicentre, national screening programme in a primary care setting	Intervention: 2472 Control: NA	Breast	Breast density scores from mammogram	High: Appointment with relevant medication
						Clinical questionnaire to calculate Tyrer-Cuzick score	Moderate: Appointment with relevant medication
Padrik 2023 ⁴⁰	Estonia	NRSI (prospective)	Single-centre screening trial in a cancer specialist center setting	Intervention: 2637 Control: NA	Breast	Polygenic risk score of 2803 single-nucleotide polymorphisms derived from gene testing	High: Earlier initiation of mammography and MRI-breast with discussion of chemoprevention therapy
							Moderate: Earlier initiation of mammography and discussion of chemoprevention therapy
							Slightly raised: Earlier initiation of mammography
							Low: Mammography from 50 years old onwards
Alterbeck 2024 ⁵⁶	Sweden	NRSI (prospective)	Multicentre, national screening trial in a primary care setting	Intervention: 999 Control: NA	Prostate	PSA test results	High: Referral to urologist with targeted and systematic biopsies
							Average: Invitation to screen in 2 years
							Low: Invitation to screen in 5 years
Dong 2024 ⁵¹	China	NRSI (prospective)	Multicentre, national screening programme in a tertiary care setting	Intervention: 946,706 Control: NA	Colorectal	FIT test results	High: Colonoscopy
						Clinical questionnaire eliciting biodata, family history of cancer, biodata, lifestyle factors, past medical history and CRC-related symptoms	Low: Return to routine screening

Study	Country	Study design	Setting	Sample size	Cancer type	Risk assessment methodology	Follow-up
Manuc 2024 ⁴³	Romania	NRSI (prospective)	Multicentre, national screening trial in a primary care setting	Intervention: 170,413 Control: NA	Colorectal	Clinical questionnaire eliciting family history of CRC and cancer syndromes, past medical history and CRC-related symptoms	High: Colonoscopy Average: FIT
Plys 2024 ³⁸	Switzerland	RCT	Single-centre screening trial in a primary care setting	Intervention: 258 Control: 257	Colorectal	Clinical questionnaire eliciting input for QCancer-Colorectal risk calculator, such as family history of cancer, biodata, CRC-related lifestyle factors, past medical history and CRC-related symptoms	High: Colonoscopy Moderate: Choice between FIT or colonoscopy Low: FIT
Tammemagi 2024 ³⁴	Canada	NRSI (prospective)	Multicentre, national screening programme in a community setting	Intervention: 7329 Control: NA	Lung	Utilised PLCO _{m2012} risk model Biodata (e.g. age, ethnicity) Family history of lung cancer Smoking history Past medical history	High: Low-dose CT scan Average: Return to routine screening
Walker 2024 ³¹	Canada	NRSI (prospective)	Multicentre, national screening programme in a primary care setting	Intervention: 4246 Control: NA	Breast	Polygenic risk score calculated from oral saliva samples Clinical questionnaire based on BOADICEA model that factors in family history of cancer, biodata, lifestyle factors and past medical history	High: Mammogram and MRI-breast Moderate: Earlier initiation of mammogram Average: Mammogram every 2 years from age 50 onwards
Yu 2024 ²⁷	China	NRSI (prospective)	Multicentre national screening programme in a primary care setting	Intervention: 9218 Control: NA	Cervical	Cytology with reference to Bethesda grading Point-of-care high-risk HPV test	High: Colposcopy and biopsy as appropriate Low: Follow-up with cytology after 3 years

BOADICEA: Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm; COPD: chronic obstructive pulmonary disease; CRC: colorectal cancer; CT: computed tomography; FIT: fecal immunochemistry test; FOBT: fecal occult blood test; HPV: human papillomavirus; iFOBT: immunochemical fecal occult blood test; MRI: magnetic resonance imaging; NA: not applicable; NRCT: non-randomised controlled trial; NRSI: non-randomised studies of intervention; PCa: prostate cancer; PLCO_{m2012}: Prostate, Lung, Colorectal, and Ovarian Model 2012; PSA: prostate serum antigen; RCT: randomised controlled trial; STHLM3: Stockholm-3 model; VDT: volume doubling time